Details for Patent: 9,700,528
Which drugs does patent 9,700,528 protect, and when does it expire?
Patent 9,700,528 protects AUVELITY and is included in one NDA.
This patent has one hundred and sixty-two patent family members in thirty-one countries.
Summary for Patent: 9,700,528
| Title: | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| Abstract: | This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed. |
| Inventor(s): | Herriot Tabuteau |
| Assignee: | Antecip Bioventures II LLC |
| Application Number: | US15/164,767 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 9,700,528
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-001 | Aug 18, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-001 | Aug 18, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,700,528
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014346807 | ⤷ Start Trial | |||
| Australia | 2015350559 | ⤷ Start Trial | |||
| Australia | 2018203638 | ⤷ Start Trial | |||
| Australia | 2019201548 | ⤷ Start Trial | |||
| Australia | 2019223187 | ⤷ Start Trial | |||
| Australia | 2019236614 | ⤷ Start Trial | |||
| Australia | 2019275593 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
